Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year forecast period. Key therapies expected to fuel growth are the recently approved CAR T-cell therapies Yescarta (Gilead / Kite), Kymriah (Novartis), and Tecartus (Gilead / Kite), as well as novel, targeted agents Polivy (Roche) and Monjuvi (MorphoSys / Incyte). In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen) and Calquence (Acerta / AstraZeneca), the Bcl-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche), and anti-CD20 monoclonal antibodies will enter the market, which will result in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the novel emerging therapies (bispecific antibody glofitamab (Roche), anti-CD19 ADC loncastuximab tesirine (ADC Therapeutics), anti-CD30 ADC Adcetris (Takeda / Seattle Genetics), and selective inhibitor of nuclear export Xpovio (Karyopharm) will further fragment the R/R DLBCL patient setting and create intense competition. Offsetting this market growth will be the biosimilar erosion expected for rituximab IV and SC, as well as the generic erosion of Celgene’s Revlimid and Janssen’s Imbruvica. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in underserved patient segments.

Questions Answered:

  • Which emerging therapies are the most promising in NHL, and what patient populations will they target? What will be their impact on the NHL market?
  • How will market share for rituximab change over the ten-year forecast period as a result of biosimilar entry? Will Roche / Genentech’s Gazyva / Gazyvaro and Rituxan Hycela / MabThera SC be able to minimize the impact of biosimilar erosion of branded rituximab?
  • The NHL therapy market will experience robust growth through 2029. What factors are driving growth in the NHL market? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 9 drugs.

Login to access report